



AGM Investor Presentation

31 May 2024

Imagion Biosystems Limited

ImagionBiosystems.com

ASX:IBX

Changing the way we look at cancer



Disclaimers

This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of Imagion or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Imagion or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.

This presentation is not a Prospectus and contains summary information about Imagion and its activities, which is current as at the date of this presentation. The information included in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor should consider when making an investment decision. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Imagion and the impact that different future outcomes may have on Imagion. This presentation has been prepared without taking account of any person's investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, make their own assessment of the information and seek legal, financial, accounting and taxation advice appropriate to their jurisdiction in relation to the information and any action taken on the basis of the information.

The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. Unless required by applicable law or regulation, no person (including Imagion) is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, currency, accuracy, reasonableness or completeness of the information contained herein. Neither Imagion nor any other person (including its shareholders, directors, officers and employees) accepts any liability and Imagion, its shareholders, its related bodies corporate and their respective directors, officers and employees, to the maximum extent permitted by law, expressly disclaim all liabilities for any loss howsoever arising, directly or indirectly, from this presentation or its contents.


This presentation includes forward-looking statements that reflect Imagion's intentions, beliefs or current expectations concerning, among other things, Imagion's results of operations, financial condition, performance, prospects, growth, strategies and the industry in which Imagion operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors, many of which are beyond the control of Imagion. Imagion cautions you that forward-looking statements are not guarantees of future performance and that its actual results of operations, financial condition, performance, prospects, growth or opportunities and the development of the industry in which Imagion operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, Imagion does not guarantee any particular rate of return or the performance of Imagion nor does it guarantee the repayment or maintenance of capital or any particular tax treatment. Investors should note that past performance may not be indicative of results or developments in future periods and cannot be relied upon as an indicator of (and provides no guidance as to) Imagion's future performance. Imagion, its related bodies corporate and each of their respective directors, officers and employees and advisers expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements in this presentation or any change in Imagion's expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.

This presentation and any materials distributed in connection with this presentation are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions.

Changing the way we look at cancer

- ✓ A **Phase I study has been completed** and the data indicate our molecularly targeted nanoparticles could be effective in detecting nodal disease in HER2 breast cancer patients when used in conjunction with conventional MRI scanners
- ✓ MagSense® imaging agents **work within current standard of care diagnosis and staging protocols with MRI systems** widely available in hospitals around the globe
- ✓ The MagSense® HER2 imaging agent is **ready to advance to Phase 2** of clinical investigation pending Investigational New Drug (IND) approval from the FDA.
- ✓ Two additional MagSense® targeted imaging agents, one for **prostate cancer** and one for **ovarian cancer**, are ready for IND enabling studies.



Leaner and Restructured

- Outsource rather than build infrastructure; use consultants and contractors.
- Pay-as-you-go matching spending to funding.
- Emphasis on performance-based compensation.

Value in our IP

- MagSense[®] is a first-of-its-kind technology to enable molecular MRI.
- The “platform” has been demonstrated with imaging agents for three different types of cancer.
- Our Phase 1 data combined with an IND approval by the FDA will be seen as a significantly de-risking and attractive to partners.

MagSense® Technology Platform

- HER2 breast cancer nodal detection is a US\$200M market with standard of care limited to detecting “suspicious nodes”.
- Prostate cancer detection is a US\$2B market with millions of biopsies performed because imaging is not the standard for diagnosis.
- Ovarian cancer remains the “silent killer” because TVUS is not sensitive enough for early detection.

Strategic Partnerships

- Big pharma and medical device companies routinely use M&A to build their portfolio.

Hologic bought Endomagnetics iron oxide tracer agent for \$300M

- Advancing through clinical investigations de-risks the technology and increases the transactional value of the technology.



www.imagionbiosystems.com

info@imagionbio.com

ASX:IBX